JPWO2022053657A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022053657A5 JPWO2022053657A5 JP2023515680A JP2023515680A JPWO2022053657A5 JP WO2022053657 A5 JPWO2022053657 A5 JP WO2022053657A5 JP 2023515680 A JP2023515680 A JP 2023515680A JP 2023515680 A JP2023515680 A JP 2023515680A JP WO2022053657 A5 JPWO2022053657 A5 JP WO2022053657A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- pharmaceutical composition
- bispecific antibody
- day
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 32
- 229960000684 cytarabine Drugs 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 229960004562 carboplatin Drugs 0.000 claims description 28
- 190000008236 carboplatin Chemical compound 0.000 claims description 28
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 28
- 229960003957 dexamethasone Drugs 0.000 claims description 28
- 229960001756 oxaliplatin Drugs 0.000 claims description 28
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 28
- 229960004641 rituximab Drugs 0.000 claims description 28
- 230000037452 priming Effects 0.000 claims description 14
- 230000003442 weekly effect Effects 0.000 claims description 14
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 10
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 10
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 8
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 claims description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- -1 rituximab Chemical compound 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 69
- 230000007935 neutral effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 229960000106 biosimilars Drugs 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076765P | 2020-09-10 | 2020-09-10 | |
| US63/076,765 | 2020-09-10 | ||
| PCT/EP2021/075021 WO2022053657A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542291A JP2023542291A (ja) | 2023-10-06 |
| JPWO2022053657A5 true JPWO2022053657A5 (https=) | 2024-09-18 |
| JP2023542291A5 JP2023542291A5 (https=) | 2024-09-18 |
Family
ID=77914294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515680A Pending JP2023542291A (ja) | 2020-09-10 | 2021-09-10 | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230355753A1 (https=) |
| EP (1) | EP4210744A1 (https=) |
| JP (1) | JP2023542291A (https=) |
| KR (1) | KR20230066581A (https=) |
| CN (1) | CN116782933A (https=) |
| AU (1) | AU2021339006A1 (https=) |
| BR (1) | BR112023004296A2 (https=) |
| CA (1) | CA3192255A1 (https=) |
| IL (1) | IL301102A (https=) |
| MX (1) | MX2023002542A (https=) |
| WO (1) | WO2022053657A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373245B (es) * | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| IL301085A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| EP4210742A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| CN121358750A (zh) | 2023-05-15 | 2026-01-16 | 金麦安博股份有限公司 | 高度纯化的艾可瑞妥单抗组合物 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| EP2155790A1 (en) | 2007-05-31 | 2010-02-24 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| CA2738568C (en) | 2008-10-01 | 2024-02-20 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN102958942A (zh) | 2009-12-29 | 2013-03-06 | 新兴产品开发西雅图有限公司 | 异二聚体结合蛋白及其应用 |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| DK2714733T3 (da) | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| MY169358A (en) | 2011-08-23 | 2019-03-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| CA2864539C (en) | 2012-02-16 | 2022-06-07 | Santarus, Inc. | Antibody formulations |
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| CA2896359A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| MX373245B (es) | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| JP2016531100A (ja) | 2013-07-12 | 2016-10-06 | ザイムワークス，インコーポレイテッド | 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物 |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| RS60739B1 (sr) | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| US20160199399A1 (en) | 2015-01-09 | 2016-07-14 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness in cancer patients |
| CN104922688A (zh) | 2015-02-10 | 2015-09-23 | 昆明贵研药业有限公司 | 奥沙利铂的环糊精复合物及制备方法 |
| WO2017210485A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| WO2018093821A1 (en) * | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| MX389244B (es) | 2017-04-27 | 2025-03-20 | Astrazeneca Ab | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer |
| BR112020015052A2 (pt) | 2018-02-09 | 2020-12-08 | Genmab A/S | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes |
| PL3886875T3 (pl) | 2018-11-30 | 2024-09-09 | Juno Therapeutics, Inc. | Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej |
| MX2022001721A (es) * | 2019-08-15 | 2022-03-11 | Genmab As | Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos. |
| CA3176436A1 (en) * | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| EP4210742A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| MX2023002541A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. |
| IL301085A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
-
2021
- 2021-09-10 AU AU2021339006A patent/AU2021339006A1/en active Pending
- 2021-09-10 US US18/025,206 patent/US20230355753A1/en active Pending
- 2021-09-10 JP JP2023515680A patent/JP2023542291A/ja active Pending
- 2021-09-10 CA CA3192255A patent/CA3192255A1/en active Pending
- 2021-09-10 EP EP21777655.8A patent/EP4210744A1/en active Pending
- 2021-09-10 IL IL301102A patent/IL301102A/en unknown
- 2021-09-10 CN CN202180069859.6A patent/CN116782933A/zh active Pending
- 2021-09-10 KR KR1020237011604A patent/KR20230066581A/ko active Pending
- 2021-09-10 MX MX2023002542A patent/MX2023002542A/es unknown
- 2021-09-10 WO PCT/EP2021/075021 patent/WO2022053657A1/en not_active Ceased
- 2021-09-10 BR BR112023004296A patent/BR112023004296A2/pt unknown
- 2021-12-22 US US17/560,006 patent/US11548952B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016606A5 (https=) | ||
| JP2020504723A5 (https=) | ||
| JP2023123627A5 (https=) | ||
| RU2007137102A (ru) | Способы лечения боли, вызванной остеоартритом, путем введения антагониста фактора роста нервов и содержащих его композиции | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2025032102A5 (https=) | ||
| CN106795219A (zh) | 抗il‑17抗体及其生产和使用的方法 | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP7702428B2 (ja) | 抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法 | |
| JP2021512107A5 (https=) | ||
| RS57708B1 (sr) | Antigen vezujući proteini specifični za p komponentu amiloida seruma | |
| JPWO2022053654A5 (https=) | ||
| JPWO2022053655A5 (https=) | ||
| JPWO2022053656A5 (https=) | ||
| JPWO2022053657A5 (https=) | ||
| JPWO2022053653A5 (https=) | ||
| JP2020505350A5 (https=) | ||
| JPWO2021224499A5 (https=) | ||
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JPWO2022053658A5 (https=) | ||
| IL319999A (en) | Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| IL314341A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
| IL314344A (en) | Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma | |
| US20160333086A1 (en) | Antigen binding proteins |